Usamos cookies propias y de terceros para mejorar tu experiencia de navegación, y ofrecerte contenidos y publicidad relevantes para ti.
11 May 2016
Barcelona, May 11, 2016 – Uriach ended the 2015 fiscal year with a consolidated turnover of €132 mn, a 10% year-on-year increase which helped the pharmaceutical company maintain double-digit growth for the second year straight. Uriach, which employs 750 people, is reporting an EBITDA of €33 mn, up 28% over the previous year.
Consumer Health (over-the-counter health and well-being products) was the fastest-growing of Uriach's four business areas, rising by 16% year-on-year (after growing by 15% last year). This increase brings Consumer Health's share of turnover up to 48% and makes Uriach a market leader in this sector. The other three business areas (Generics, Branded Products and CMOs) recorded a combined growth of 7.5%. These areas, which focus on licensing, generics and contract manufacturing, represent 52% of Uriach's business.
The highlights of 2015 included the acquisitions of Fisiocrem and the Italian pharmaceutical company Laborest, which are part of Uriach's 2013–2017 Strategic Plan and drive the company's organic growth through buy-outs, acquisitions and international expansion. Along the same line, Fisiocrem, one of the creams most widely used by athletes and physiotherapists to prevent and relieve muscle pain, posted a sell-out turnover of €6.7 million in 2014, with annualised growth over 70%. Furthermore, the acquisition of Laborest, a key pharmaceutical company in the Italian market for food supplements offered for sale through visits to medical professionals, will boost turnover by close to €25 mn and represents a significant milestone in Uriach's internationalisation drive.
Similarly, apart from entering the Italian market with the acquisition of Laborest, 2015 saw Uriach start commercial operations in Portugal with its own business network and a focus on the Aquilea and Innovage brands (nutricosmetics). The pharmaceutical company now sells its products in over 70 countries in the key parts of the world, while international markets have increased their share of total turnover from just over 30% in 2012 to 48% in 2016.
Uriach expects to grow by 10 to 15% in 2016, which would take its turnover to €150 mn and its EBITDA close to €40 mn. According to Uriach CEO Oriol Segarra, "Having fulfilled almost two thirds of the 2013–2017 Strategic Plan, the results we have achieved so far make us even more confident that we will attain the goals set out in the plan. With two years to go, the forecast for this fiscal year is extremely positive and, in line with the two previous years, close to double-digit growth".